Newsroom

Sorted by: Latest

-

DualEntry Launches Native Two-Way Integration With Expensify

NEW YORK--(BUSINESS WIRE)--DualEntry has launched a native, two-way integration with Expensify, bringing expenses, corporate card spend, reimbursements, and accounting data into one connected workflow.Finance teams using both platforms can now connect Expensify directly to DualEntry and keep data synced automatically, without exporting CSVs or manually re-entering transactions.With the integration:DualEntry’s chart of accounts syncs into Expensify as categoriesClassifications sync as tags, with...
-

Quantum XChange Joins the Cisco Networking App Marketplace as a Cisco Technology Partner

BETHESDA, Md.--(BUSINESS WIRE)--Quantum XChange brings FIPS-validated post-quantum cryptography to Cisco networks, enabling quantum-safe security and crypto-agility via Phio TX-EM....
-

ASB Capital Launches Global Multi-Asset Fund with Principal Asset Management®

DUBAI, United Arab Emirates--(BUSINESS WIRE)--ASB Capital Launches Global Multi-Asset Fund with Principal Asset Management...
-

Extreme Networks Schedules First Quarter 2027 Financial Results Conference Call

MORRISVILLE, N.C.--(BUSINESS WIRE)--Extreme will release financial results for its first fiscal quarter 2027, ended September 30, 2026, before market open on Wednesday, October 28, 2026....
-

Convenience Store Satisfaction Slides as App Quality and Store Conditions Can’t Keep Pace With Expanding Offerings, ACSI Data Show

ANN ARBOR, Mich.--(BUSINESS WIRE)--Customer satisfaction among convenience stores drops, according to the American Customer Satisfaction Index's Convenience Store Study 2026....
-

IFF Identifies the Life-Stage Insights Shaping Dairy’s Future

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF)—a global leader in flavors, fragrances and health and biosciences, published its latest resource, Dear Dairy: The Life Stages Guide. This strategic guide reveals how manufacturers can unlock new opportunities by aligning dairy innovation with consumers' evolving needs throughout life. “Dairy is one of the few categories that evolves alongside consumers throughout their lives,” said Rogerio de Almeida Prado, vice president of Global Dairy & BBC (Bak...
-

Dunkin’® Assembles with Marvel Studios’ “Avengers: Doomsday” for an Epic New Menu and Limited-Edition Collectibles

BOSTON--(BUSINESS WIRE)--The countdown to Doomsday has begun. Starting Nov. 4, Dunkin’ and Marvel Studios’ “Avengers: Doomsday” will collide in a limited-time lineup of character-inspired drinks, donuts and collectibles at participating Dunkin’ restaurants nationwide. This is only the beginning, with more surprises to be announced at the top of November. A Menu Assembled for Every Fan The limited-time beverage lineup includes: Iced Captain’ccino: Espresso, caramel flavor and coffee milk, lightl...
-

Arboretum Launches to Redefine Precision Medicine for Common Diseases as a Next-Generation Molecular Information Company

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Arboretum LifeSciences, Inc., a next-generation molecular information company, launched today with a mission to make precision medicine a reality for some of the most common diseases that impact patients around the world. Founded by leaders in data science from the Broad Institute, Arboretum’s approach integrates AI and genetic testing to expand access to genomic medicine for patients and enable recruitment of genomically profiled patients for clinical researc...
-

insitro Designed Machine Learning Models for Small Molecule in vivo Pharmacokinetic Behavior Prediction Now Available in Lilly TuneLab

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, the AI company unlocking causal human biology to systematically generate high-impact therapeutics, today announced that the advanced machine learning models that insitro built with Eli Lilly and Company (Lilly) to predict in vitro and, critically, in vivo properties of small molecules can now be used by certain biotech companies in Lilly TuneLab™. Trained on multi-species preclinical data that Lilly generated over decades of research from hu...
-

CatalYm to Present Updated GDFATHER-NEO Clinical Data and Highlight Ongoing Phase 2b Visugromab Trials at ESMO 2026

MUNICH & SAN FRANCISCO--(BUSINESS WIRE)--CatalYm today announced that updated clinical results from its Phase 2 GDFATHER-NEO trial will be presented in a rapid oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain. The oral presentation will feature updated findings from the Phase 2 GDFATHER-NEO trial (NCT06059547) and will include final pathological and radiological outcomes as well as event-free survival from th...